Hydralazine hydrochloride

Name: Hydralazine hydrochloride
Brand: MedChemExpress
SKU: HY-B0464
Rating: 5.0 (3 reviews)

Cat. No.: HY-B0464 Purity: 99.97%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Hydralazine hydrochloride is an antihypertensive agent. Hydralazine hydrochloride can inhibit mitochondrial fission and human peritoneal mesothelial cell proliferation. Hydralazine hydrochloride has immunomodulation and anti-migratory effect. Hydralazine hydrochloride activates the intrinsic pathway of apoptosis and causes DNA damage.

For research use only. We do not sell to patients.

Hydralazine hydrochloride Chemical Structure

CAS No. : 304-20-1

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water ready for reconstitution	USD 33	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in Water	USD 33	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	USD 30	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 90	In-stock	Estimated Time of Arrival: December 31
1 g		Get quote
5 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Hydralazine hydrochloride:

Hydralazine-d₄ hydrochloride Get quote
Hydralazine-d₅ hydrochloride Get quote
Hydralazine Get quote
Hydralazine hydrochloride (Standard) Get quote

2 Publications Citing Use of MCE Hydralazine hydrochloride

: Hydralazine hydrochloride purchased from MedChemExpress. Usage Cited in: Neurosci Bull. 2020 Oct;36(10):1158-1170. [Abstract]; Western blots (left) and analysis (right) of cyto-Drp1, mito-Drp1, and T-Drp1 in different groups of mice. Hydralazine (acrolein scavenger) suppresses the translocation of Drp1 and alleviates the morphological disruption of mitochondria after ICH in mice.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim

View All Caspase Isoform Specific Products:

View All Isoforms

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Bcl-2

Bcl-xL

Caspase-8

Caspase-9

Caspase 3

In Vitro

Hydralazine hydrochloride (40-600 μM, 24-48 h) induces caspase-dependent apoptosis and activates mitochondrial apoptotic events in leukemic T cells^[1].
Hydralazine hydrochloride (1 μM, 40 min) prevents H₂O₂-induced mitochondrial fragmentation and depolarization in ATCC-CCL2 cells^[2].
Hydralazine hydrochloride (3-100 μg/mL, 1-5 days) inhibits human peritoneal mesothelial cell proliferation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	Human peritoneal mesothelial cell (HPMC)
Concentration:	3μg/mL, 6 μg/mL, 12 μg/mL, 25 μg/mL, 50 μg/mL, 100 μg/mL
Incubation Time:	5 days
Result:	Caused a dose-dependent inhibition of HPMC growth.

Apoptosis Analysis^[3]

Cell Line:	Jurkat, CEM-6, MOLT-4
Concentration:	40 μM, 80 μM, 200 μM, 400 μM, 600 μM
Incubation Time:	16 h, 24 h, 48 h
Result:	Observed significant apoptosis in Jurkat and MOLT-4 cells at concentrations of 200 μM. Induced a slight decrease in DNMT1 protein expression at 24 hr and nearly a complete loss after 48 hr. Observed proteolytic processing of the initiator caspases-8 and -9, as well as cleavage of the effector caspase-3. Resulted in generation of ROS and disruption of ΔΨm in Jurkat cells. Observed that overexpression of Bcl-2 and Bcl-xL proteins prevented cell death.

In Vivo

Hydralazine hydrochloride (5 mg/kg, Intraperitoneal injection, once a day for 4-6 weeks) plays an immunomodulation role of pro-regeneration in Spinal cord injury mice^[4].
Hydralazine hydrochloride (14 mg/kg, supplemented in drinking water for 15 days) reduces leukocyte migration in spontaneously hypertensive and normotensive rats^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Spinal cord injury mice^[4]
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	Improved not only motor function and hypersensitivity but also spontaneous pain and emotion response in SCI mice. Inhibited both of BMDM recruitment and acrolein accumulation in the lesion epicenter of spinal cord in mice.

Animal Model:	Spontaneously hypertensive rats (SHR)^[5]
Dosage:	14 mg/kg
Administration:	Supplemented in drinking water
Result:	Reduced systolic blood pressure values and the number of adherent and migrating leukocytes in SHR. Reduce the number of adherent and migrating leukocytes in SHR. Decreased the levels of ICAM-1 mRNA.

Clinical Trial

Molecular Weight

196.64

Formula

C₈H₉ClN₄

CAS No.

304-20-1

Appearance

Solid

Color

White to off-white

SMILES

NNC1=NN=CC2=C1C=CC=C2.Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 25 mg/mL (127.14 mM; Need ultrasonic)

DMSO : 25 mg/mL (127.14 mM; ultrasonic and adjust pH to 11 with NaOH; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.0854 mL	25.4272 mL	50.8544 mL
5 mM	1.0171 mL	5.0854 mL	10.1709 mL
10 mM	0.5085 mL	2.5427 mL	5.0854 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (10.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (10.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 8.33 mg/mL (42.36 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.97%

Select Batch:

Data Sheet (281 KB) SDS (480 KB)

COA (249 KB) RP-HPLC (242 KB)

Handling Instructions (2659 KB)

References

[1]. Fang C C, et al. Hydralazine inhibits human peritoneal mesothelial cell proliferation and collagen synthesis [J]. Nephrology Dialysis Transplantation, 1996, 11(11): 2276-2281. [Content Brief]

[2]. Kalkhoran S B, et al. Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission [J]. Cardiovascular Research, 2022, 118(1): 282-294. [Content Brief]

[3]. Ruiz-Magaña M J, et al. The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells [J]. Oncotarget, 2016, 7(16): 21875. [Content Brief]

[4]. Quan X, et al. Hydralazine plays an immunomodulation role of pro-regeneration in a mouse model of spinal cord injury [J]. Experimental Neurology, 2023, 363: 114367. [Content Brief]

[5]. Rodrigues S F, et al. Hydralazine reduces leukocyte migration through different mechanisms in spontaneously hypertensive and normotensive rats [J]. European journal of pharmacology, 2008, 589(1-3): 206-214. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	5.0854 mL	25.4272 mL	50.8544 mL	127.1359 mL
	5 mM	1.0171 mL	5.0854 mL	10.1709 mL	25.4272 mL
	10 mM	0.5085 mL	2.5427 mL	5.0854 mL	12.7136 mL
	15 mM	0.3390 mL	1.6951 mL	3.3903 mL	8.4757 mL
	20 mM	0.2543 mL	1.2714 mL	2.5427 mL	6.3568 mL
	25 mM	0.2034 mL	1.0171 mL	2.0342 mL	5.0854 mL
	30 mM	0.1695 mL	0.8476 mL	1.6951 mL	4.2379 mL
	40 mM	0.1271 mL	0.6357 mL	1.2714 mL	3.1784 mL
	50 mM	0.1017 mL	0.5085 mL	1.0171 mL	2.5427 mL
	60 mM	0.0848 mL	0.4238 mL	0.8476 mL	2.1189 mL
	80 mM	0.0636 mL	0.3178 mL	0.6357 mL	1.5892 mL
	100 mM	0.0509 mL	0.2543 mL	0.5085 mL	1.2714 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.